Get our Free Patent Expiration, Litigation, and Drug Price Updates

Serving hundreds of leading biopharmaceutical companies globally:

Accenture
UBS
Cantor Fitzgerald
QuintilesIMS
Healthtrust
Daiichi Sankyo

Generated: May 27, 2019

DrugPatentWatch Database Preview

Litigation Details for Allergan Inc. v. Alcon Inc. (D. Del. 2004)

« Back to Dashboard

Allergan Inc. v. Alcon Inc. (D. Del. 2004)

Docket ➤ Try a Free Trial Date Filed 2004-08-24
Court District Court, D. Delaware Date Terminated 2006-03-07
Cause 28:1338 Patent Infringement Assigned To Gregory Moneta Sleet
Jury Demand Plaintiff Referred To
Parties ALCON INC.; ALCON LABORATORIES, INCORPORATED; ALCON RESEARCH LTD.; ALLERGAN INC.; ALLERGAN SALES LLC
Patents 4,089,969; 4,260,769; 4,382,892; 4,474,787; 4,971,998; 5,089,509; 5,134,127; 5,202,128; 5,212,196; 5,376,645; 5,474,979; 5,688,819; 5,736,165; 5,834,011; 5,922,695; 5,977,089; 6,043,230; 6,153,592; 6,204,257; 6,248,741; 6,562,873; 6,627,210; 6,641,843; 6,673,337
Attorneys Glenn Christopher Mandalas; Josy W. Ingersoll; Karen Elizabeth Keller; Melanie K. Sharp; Sean Paul Hayes; William J. Marsden , Jr.
Link to Docket External link to docket
Biologic Drugs cited in Allergan Inc. v. Alcon Inc.
The biologic drug covered by the patents cited in this case is ➤ Try a Free Trial .

Details for Allergan Inc. v. Alcon Inc. (D. Del. 2004)

Date Filed Document No. Description Snippet Link To Document
2005-07-06 100 Exhibit Exhibits used by Defendants at the Markman Hearing 6/29/05 !9? ......... 5 US Patent 6,627,210 9/30/03 U.S.Patent 6,641,834 lm’m-§_ US Patent 6,673,337 l gm …gmnimmqummul 1111 Patent Number: 5,215,991 [4'5] Date of Patent: . Jiin. 1, 1993 FOREIGN PATENT DOCUMENTS…The Prosecution Histor_'y Of The ’210 Patent The ’210 patent issued on September 30, 2003 directly from… double patenting rejection because the conflicting claims have not in fact 'been patented. $})ecz…35 USC 103 as obvious over US Patent 5,2~15,991 (th'e` »“Burke” patent) in view of Re_mingwn’s . Pharmaceutical External link to document
2005-07-25 107 Exhibit Exhibit A Background 41. The patents most relevant to this suit include: a. U.S. Patent No. 6,627,210 (hereinafter “…Background 41. The patents most relevant to this suit include a. U.S. Patent No. 6,627,210 (hereinafter “the…United States Patents Nos. 6,641,834 (“the '834 patent”) and 6,673,337 (“the '337 patent”). The Parties…United States Patent Nos. 6,641,834 (the “’834 patent”) and 6,673,337 (the “’337 patent”) invalid, not…Burke (U.S. Patent No. 5,215,991) in view of Beck et al. (U.S. Patent No. 6358935). The Patent Examiner External link to document
2005-08-09 115 Answering Brief in Opposition might stick. With regard to U.S. Patent No. 6,627,210 (which is not even in suit), Alcon accuses…contends that both of the patents-in-suit in this case, as well as a parent patent, are products of a vast… inventors of the patents-in-suit, and one of the attorneys prosecuting the patents-in-suit to “defraud…non-infringement of the ’ 337 patent and one on lack of written description of the ’ 874 patent. These motions were…on the ’ 834 patent.” (D.I. 107, at 3.) That is akin to Allergan asserting a new patent against Alcon External link to document
2005-08-09 116 Exhibit A-C [1l 27124 approaches [11 24:6 beneficial 111 4:5 834[11 24.24 a so ute yu 2 .9 _ _ '91] [1] 4~10 21…quot;" Dn‘“'°“ 10 three patents that are at issue -- three patents that are 11 Mond=\y, Novembe.…cyclodextrin. 'lhat phrase is in that patent 3 regard to the main patent there1 again it's simply a matter… '337 patent 24 That is what we seek here Whar we would like to 25 T'he other patent came off …application of that same 20 patents wcrc actually never addressed Indeed, if you go 21 patent 21 into lodge Carter External link to document
Date Filed Document No. Description Snippet Link To Document

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cantor Fitzgerald
Medtronic
Citi
Farmers Insurance
Mallinckrodt
Daiichi Sankyo

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.